NCT06125314View on ClinicalTrials.gov

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

CompletedOBSERVATIONAL
Enrollment

517

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Breast NeoplasmsBreast CancerBreast CarcinomaGenesHER2
Trial Locations (7)

Unknown

Research Site, Kuwait City

Research Site, Doha

Research Site, Mecca

Research Site, Riyadh

Research Site, Abu Dhabi

Research Site, Al Ain City

Research Site, Dubai

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY